Sarcopenic Factors May Have No Impact on Outcomes in Ovarian Cancer Patients

Abstract

Although the prognostic value of sarcopenic factors, such as loss of muscle mass and quality, have been widely reported in patients with cancer during the last decade, the value in those with ovarian cancer remains unclear. Therefore, this study evaluated the prognostic impact of sarcopenic factors in patients with ovarian cancer. We retrospectively evaluated the data of 94 ovarian cancer patients who underwent surgery and chemotherapy at the Shimane University Hospital between March 2006 and 2013. Preoperative computed tomography scan at the level of the third lumbar vertebra was used to evaluate skeletal muscle volume and quality based on the skeletal muscle index (SMI) and intramuscular adipose tissue content (IMAC), respectively. The impact of preoperative SMI and IMAC on outcomes was subsequently investigated. Low SMI and high IMAC were not significantly associated with disease-free survival (p = 0.329 and p = 0.3370, respectively) or poor overall survival (p = 0.921 and p = 0.988, respectively). Neither preoperative low muscle volume nor low muscle quality was a poor prognostic factor in ovarian cancer.

Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma

“…Most studies were conducted in Western populations whose body composition is different from that of Asians. Recently, a Japanese retrospective study showed results similar to those of our study; pre-treatment SMI was not associated with ovarian cancer patients' PFS and OS [19]. However, that study included early-stage disease and histologic types other than HGSOC, which is definitely different compared to our study.…”

Skeletal muscle mass as a prognostic indicator of outcomes in ovarian cancer: a systematic review and meta-analysis

“…The flow diagram is illustrated in Figure 1. Fifteen studies6–12 20–27 were included in this systematic review, of which six studies were included in the meta-analysis 6–12. (Online supplementary Table S2 lists all excluded studies9 18 28–33 and the reasons for exclusion.…”

“…The sample size ranged from 7420 to 323 patients 12. Three studies were performed in Germany,7 12 27 three in The Netherlands,9–11 five in the USA,12 20 23 25 26 three in Japan,21 22 24 and one in Austria 10. Fourteen studies were retrospective and one was prospective 20.…”

“…Ten of 15 studies reported a body mass index (median or mean) of 24.96 to 28.023 (kg/m 2 ). In 9 of 15 studies,6–8 10 12 21–23 26 patients underwent primary debulking surgery, followed by chemotherapy, two studies reported patients undergoing interval debulking surgery followed by chemotherapy,13 15 and in four studies patients underwent chemotherapy only 20 24 25 27. In all studies, more than 50% of patients had advanced ovarian cancer (stages III/IV).…”

“…In all studies, more than 50% of patients had advanced ovarian cancer (stages III/IV). Ten studies6–10 12 22 25–27 assessed skeletal muscle index at baseline, as a continuous variable in two studies26 27 or as a dichotomous variable with specific cut-off values in eight studies 6–10 12 22 25. Four studies assessed skeletal muscle radiodensity,6 8 10 12 as a continuous variable in one study8 or as dichotomous variable defined with specific cut-off values,6 10 12 four studies9 11 20 21 assessed skeletal muscle area, and four studies11 21 23 24 assessed psoas outcomes.…”